FDA vaccine head will step down in April after string of controversial decisions
CNBC
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the agency following multiple decisions that raised concerns within the industry.
Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesperson confirmed on Friday. It is his second departure from the position: He briefly left the post in July following backlash over his regulatory decisions, and returned only two weeks later in August.
In a post on X, FDA Commissioner Marty Makary said the FDA will appoint a successor before Prasad returns next month to the University of California San Francisco, where he taught before taking the FDA position last year. Makary said Prasad "got a tremendous amount accomplished" during his tenure at the agency.
Home sales made a small gain to start the year, but higher mortgage rates now could throw cold water on the spring season.
The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.
Lego on Tuesday reported a 12% jump in revenue for fiscal year 2025 and reported consumer sales that far outpace the broader toy industry.
Live Nation, which owns Ticketmaster, reached a settlement with the Department of Justice over antitrust concerns.
A growing number of consumers are seeking out third spaces and membership clubs surrounding wellness, to improve their health while also socializing.
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
A closely watched barometer for used vehicle pricing jumped last month as dealers sped to increase inventories amid optimism of a robust spring selling season.
Gap has been on a steady upswing of growth but saw worse than expected results during its holiday quarter after historic winter storms led to store closures.
Frustrated sellers who pulled homes off the market last fall are now re-listing them at a quick pace, thanks to lower mortgage rates, but supply is still low.
Travelers who are far from falling missiles, drone attacks and other geopolitical flashpoints aren't immune to ripple effects.
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
Target's merchandising leaders previewed the company's ambitious plans to overhaul key categories, including home and apparel, at an investor meeting.